Biotech Values

[DewDiligence]

Re: Vioxx woes

PFE is sitting pretty in the COX-2 space now. Vioxx is gone and Arcoxia, MRK’s other COX-2, is probably dead in the U.S. Even if Arcoxia has merit medically, I can’t see the FDA approving another COX-2 from MRK.

Meanwhile, NVS’ Prexige is on hold, both in the U.S. and Europe (#msg-4691249).

It’s hard to imagine a more fortuitous COX-2 scenario for PFE than what has actually occurred.